The TGI model accurately predicts tumor shrinkage (RE < 20%) in HER2+ breast cancer cell line after the administration of 1 and 10 mg/kg BW of MBQ-167 three times a week for 65 days in mice, with a relative tumor size reduction of 94.3% at the highest dose level. Here, ERBB2 is linked to breast carcinoma.